These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 18174037)

  • 1. Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era.
    Lavie CJ; Milani RV
    J Am Coll Cardiol; 2008 Jan; 51(1):56-8. PubMed ID: 18174037
    [No Abstract]   [Full Text] [Related]  

  • 2. ["The lower LDL cholesterol levels, the better" still valid. Negative/neutral conclusions of three studies on statins do not change the clinical practice].
    Olsson AG; Nilsson PM
    Lakartidningen; 2009 Mar 18-24; 106(12):854-7. PubMed ID: 19452786
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol.
    deGoma EM; Leeper NJ; Heidenreich PA
    J Am Coll Cardiol; 2008 Jan; 51(1):49-55. PubMed ID: 18174036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).
    Cui Y; Watson DJ; Girman CJ; Shapiro DR; Gotto AM; Hiserote P; Clearfield MB
    Am J Cardiol; 2009 Sep; 104(6):829-34. PubMed ID: 19733719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDL: back to the drawing board.
    Johns Hopkins Med Lett Health After 50; 2007 May; 19(3):1-2. PubMed ID: 17657883
    [No Abstract]   [Full Text] [Related]  

  • 6. Keeping our eyes on the prize: low density lipoprotein cholesterol.
    de Lemos JA; Khera A
    Am J Cardiol; 2009 Dec; 104(12):1697-8. PubMed ID: 19962478
    [No Abstract]   [Full Text] [Related]  

  • 7. Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors?
    Miura S; Saku K
    J Hypertens; 2010 Aug; 28(8):1614-6. PubMed ID: 20647856
    [No Abstract]   [Full Text] [Related]  

  • 8. High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench.
    Levy Y
    Cardiovasc Res; 2008 Mar; 77(4):614-5. PubMed ID: 18187459
    [No Abstract]   [Full Text] [Related]  

  • 9. LDL-Cholesterol is the King.
    Goumas GS
    Angiology; 2009; 60(3):387-8. PubMed ID: 19497926
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical trials and tribulations. Cholesterol veers off script.
    Couzin J
    Science; 2008 Oct; 322(5899):220-3. PubMed ID: 18845747
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of cholesteryl ester transfer protein inhibitor on vitamin E transport should be studied.
    Masterjohn C
    Am Heart J; 2009 Jul; 158(1):e11; author reply e13. PubMed ID: 19540377
    [No Abstract]   [Full Text] [Related]  

  • 12. Dissociating HDL cholesterol from cardiovascular risk.
    Hausenloy DJ; Opie L; Yellon DM
    Lancet; 2010 Jul; 376(9738):305-6. PubMed ID: 20655104
    [No Abstract]   [Full Text] [Related]  

  • 13. Achieving cholesterol goals. Current and future drug therapies.
    Jones PH
    Postgrad Med; 2003 Aug; 114(2 Suppl):14-21. PubMed ID: 19667635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medications that lower low-density lipoprotein (LDL) cholesterol and non–high-density lipoprotein (non-HDL) cholesterol.
    Brown WV
    J Clin Lipidol; 2012; 6(2):95. PubMed ID: 22385540
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raising high-density lipoprotein: for better or worse?
    Tomlinson B
    Heart; 2010 Sep; 96(17):1339-40. PubMed ID: 20801851
    [No Abstract]   [Full Text] [Related]  

  • 17. Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins.
    Barter PJ; Rye KA
    Circulation; 2006 Sep; 114(12):1315-20; discussion 1320. PubMed ID: 16982953
    [No Abstract]   [Full Text] [Related]  

  • 18. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphism of the cholesteryl ester transfer protein gene.
    Dullaart RP; van Tol A
    N Engl J Med; 1998 May; 338(22):1625-6. PubMed ID: 9606121
    [No Abstract]   [Full Text] [Related]  

  • 20. The case for medical treatment in chronic stable coronary artery disease.
    Nash DT
    Arch Intern Med; 2005 Dec 12-26; 165(22):2587-9, discussion 2593-4. PubMed ID: 16344414
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.